Upton votes for legislation to lower drug prices
WASHINGTON, D.C. – U.S. Rep. Fred Upton, R-St. Joseph, today voted to pass H.R. 1503, the Orange Book Transparency Act of 2019, and H.R. 1520, the Purple Book Continuity Act of 2019, legislation aimed at lowering the cost of generic drugs and boosting competition in the market place.
“Drug prices are too expensive for too many Americans. We know that, and I’m glad that Congress is taking some important steps to help reduce the cost of prescription drugs,” Upton said. “But we do have more to do, we know that, too. The legislation we passed today in the House was bipartisan, and I’d encourage my colleagues on both sides of the aisle to continue working together on solutions that help Americans better afford their drugs and their treatment.”
Both bills passed in March out of the Health Subcommittee, which Fred sits on.
H.R. 1503, introduced by Rep. Robin Kelly (D-IL), would help ensure timely and accurate updates to the Orange Book. The legislation also requires manufacturers to share information with the FDA, ensures that patents listed in the Orange Book are relevant to the approved drug product, and requires manufacturers to notify the FDA of any court decision finding a patent invalid so the FDA can remove the patents from the Orange book.
H.R. 1520, introduced by Rep. Anna G. Eshoo (D-CA), would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book, helping to make it more transparent and helpful. The legislation would also specify that the Purple Book should be published electronically on the FDA’s website and updated routinely, and direct FDA to consider the types of patents that should be listed in the Purple Book.